spacer spacer

spacer

David Huntsman

  • Associate Professor - University of British Columbia, Faculty of Medicine - since 2005
  • Genetic Pathologist - British Columbia Cancer Agency, Department of Pathology and Laboratory Medicine - since 1999
  • Research Affiliate - Vancouver General Hospital, The Prostate Research Centre - since 2000
  • Director - DNA Diagnostic Laboratory, British Columbia Childrenís Hospital - 1999-2000
  • Honorary Visiting Fellow - University of Cambridge, UK - 1997-1999

POST-SECONDARY EDUCATION
  • MD - Memorial University Newfoundland, Canada (1984-1988)

SPECIAL PROFESSIONAL QUALIFICATIONS
  • Clinical Oncology/Cancer Genetics - University of Cambridge, UK (1997-1999)
  • FCCMG Clinical Molecular Genetics - Canadian College of Medical Genetics, Canada (1995-1997)
  • FRCPC General Pathology - Royal College of Physicians and Surgeons, Canada (1991-1995)
  • Anatomic and Clinic Pathology Boards - American Pathology Boards, USA (1991-1995)
  • LMCC - Medical Council of Canada (1991)

COMMITTEE MEMBERSHIPS
  • Ontario Institute for Cancer Research, Genomics/Bioinformatics Advisory Panel, March 2009 -
  • VCHRI - In It For Life, Clinical Investigator Award Search Committee, November 2008 -
  • Marsha Rivkin Center, Think Tank Steering Committee, November 2008 -
  • Hereditary Diffuse Gastric Cancer Cambridge Workshop Organizing Committee, 2008
  • Canadian Cancer Research Alliance/International Cancer Genome Consortium Strategic Planning Subcommittee, 2008 - present
  • Ovarian Cancer Canada, Grants Review Panel, 2008 - present
  • Marsha Rivkin Center, Scientific Advisory Board Member, 2008 - present
  • National Cancer Institute, Panel J2 Chair, 2008 - present
  • Terry Fox Research Institute Advisory Committee, 2006 - present
  • The Cancer Genome Atlas, Ovarian Cancer Working Group Member, 2007 - present
  • BC Proteomics Network Organizing Committee, 2007
  • BCCRC Noon Seminar Series Committee, 2007 - present
  • BCCRC Awards, Scholarships, Bursaries Committee, 2007 - present
  • USCAP Education Committee, 2005 - present
  • MSFHR Research Advisory Council, 2005 - present
  • Canadian Medical Association, 2005 - present
  • BCCA Gynecology Executive Committee, 2005 - present
  • Diagnostic Accreditation Program, 2005
  • Ontario Cancer Research Network, 2005
  • National Cancer Institute of Canada, Panel J
  • MSFHR Scientific Advisory Committee, 2004 - present
  • MSFHR Clinical Trainee Evaluation Committee, 2003 - 2006
  • Diagnostic Accreditation Program: Molecular Pathology Group, 2000 - present
  • BCIT Advisory Committee for the Genetic Technology Training Program, Chair, 2000 - 2002
  • BCCA Hereditary Cancer program Steering Committee, 1999 - present
  • BC Diagnostic Accreditation Molecular Pathology Working Group, 1999 - present
  • BCCA Guidelines and Protocols Committee (Hemochromatosis), 1999 - present
  • BCMA Protocols and Guidelines Committee (Hemochromatosis), 1999 - 2001
  • Member of Panel J Review Committee National Cancer Institute of Canada

AWARDS AND DISTINCTIONS
  • Vancouver General Hospital - Scientific Achievement Award (2005)
  • Marsha Rivkin Centre Scientific Scholar Award (2004)
  • Medical Advisory Council - Scientific Achievement Award (2004)
  • Canadian Society for Clinical Investigation: Joe Doupe Young Investigator's Award (2004)
  • Research and Discovery Award, Pathology Day, UBC (2003)
  • Michael Smith Career Investigator Award - Michael Smith Foundation (2002)
  • Benjamin Castleman Award, United States and Canadian Academy of Pathology and Society for Pediatric Pathology, Chicago (2002)
  • VP Research: Faculty Development Award - BCCA: Simon Sutcliffe (2001)
  • Translational Research Award - Start up funds - UBC Department of Pathology (2001)
  • VP Research: Faculty Development Award - UBC: VP Research (2001)
  • McLaughlin Fellowship $45,000 x 2 years - UBC (1997)
  • Resident Research Award - UBC (1994)
  • Residents Research Prize - MRC of Canada, Canadian Society of Clinical Researchers (1994)
  • Pathology Prize 1986 for best marks in the first and second year pathology courses - Memorial University of Newfoundland (1986)
  • Newfoundland Medical Association Scholarship 1986 for scholastic excellence and community involvement - Memorial University of Newfoundland (1986)

SELECTED PUBLICATIONS
Journals
  1. Jamshidi F, Pleasance E, Li Y, Shen Y, Kasaian K, Corbett R, Eirew P, Lum A, Pandoh P, Zhao Y, Schein JE, Moore RA, Rassekh R, Huntsman DG, Knowling M, Lim H, Renouf DJ, Jones SJ, Marra MA, Nielsen TO, Laskin J, Yip S. (2014-05-07). Diagnostic value of next-generation sequencing in an unusual sphenoid tumor. Oncologist. 19(6),623
  2. Singh N, Gilks CB, Huntsman DG, Smith JH, Coutts M, Ganesan R, McCluggage WG. (2014-04-01). Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status. Histopathology. 64(5),626
  3. Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Prat J, D'Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM. (2014-03-23). Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 0(0),0
  4. Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD. (2014-03-13). Better Therapeutic Trials in Ovarian Cancer. J Natl Cancer Inst. 106(4),29
  5. Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, Huntsman DG, Köbel M, Lee CH. (2014-03-01). Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor. Histopathology. 64(4),585
  6. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS. (2014-02-22). A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer. 14(1),120
  7. Kommoss S, Gilks CB, Penzel R, Herpel E, Mackenzie R, Huntsman D, Schirmacher P, Anglesio M, Schmidt D, Kommoss F. (2014-02-01). A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. Histopathology. 64(3),380
  8. McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, Gilks CB, Finlayson SJ, Huntsman DG, Miller DM; Ovarian Cancer Research Program of British Columbia. (2014-01-09). Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol. 210(5),471
  9. McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. (2014-01-01). Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 27(1),128
  10. Townsend KN, Spowart JE, Huwait H, Eshragh S, West NR, Elrick MA, Kalloger SE, Anglesio M, Watson PH, Huntsman DG, Lum JJ. (2013-12-23). Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. PLoS One. 8(12),82406
  11. Witkowski L, Mattina J, Schönberger S, Murray MJ, Choong CS, Huntsman DG, Reis-Filho JS, McCluggage WG, Nicholson JC, Coleman N, Calaminus G, Schneider DT, Arseneau J, Stewart CJ, Foulkes WD. (2013-11-12). DICER1 hotspot mutations in non-epithelial gonadal tumours. Br J Cancer. 109(10),2744
  12. Kommoss S, Gilks CB, Kommoss F, Chow C, Hilpert F, du Bois A, Köbel M, Huntsman DG, Anglesio M, Kalloger SE, Pfisterer J. (2013-11-01). Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. Histopathology. 63(5),704
  13. Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, Wechsler J, Yang J, Hayes J, Klein RJ, Zhang J, Wei L, Wu G, Rusch M, Nagahawatte P, Ma J, Chen SC, Song G, Cheng J, Meyers P, Bhojwani D, Jhanwar S, Maslak P, Fleisher M, Littman J, Offit L, Rau-Murthy R, Fleischut MH, Corines M, Murali R, Gao X, Manschreck C, Kitzing T, Murty VV, Raimondi SC, Kuiper RP, Simons A, Schiffman JD, Onel K, Plon SE, Wheeler DA, Ritter D, Ziegler DS, Tucker K, Sutton R, Chenevix-Trench G, Li J, Huntsman DG, Hansford S, Senz J, Walsh T, Lee M, Hahn CN, Roberts KG, King MC, Lo SM, Levine RL, Viale A, Socci ND, Nathanson KL, Scott HS, Daly M, Lipkin SM, Lowe SW, Downing JR, Altshuler D, Sandlund JT, Horwitz MS, Mullighan CG, Offit K. (2013-10-01). A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 45(10),1226
  14. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG. (2013-09-04). Type-specific cell line models for type-specific ovarian cancer research. PLoS One. 8(9),72162
  15. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, Yang W, McConechy M, Melnyk N, Anglesio M, Luk MT, Tse K, Zeng T, Moore R, Zhao Y, Marra MA, Gilks B, Yip S, Huntsman DG, McAlpine JN, Shah SP. (2013-09-01). Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 231(1),21
  16. Witkowski L, Lalonde E, Zhang J, Albrecht S, Hamel N, Cavallone L, May ST, Nicholson JC, Coleman N, Murray MJ, Tauber PF, Huntsman DG, Schönberger S, Yandell D, Hasselblatt M, Tischkowitz MD, Majewski J, Foulkes WD. (2013-09-01). Familial Rhabdoid Tumour "Avant La Lettre" - from pathology review to exome sequencing and back again. J Pathol. 231(1),35
  17. McCluggage WG, Singh N, Kommoss S, Huntsman DG, Gilks CB. (2013-09-01). Ovarian Cellular Fibromas Lack FOXL2 Mutations: A Useful Diagnostic Adjunct in the Distinction From Diffuse Adult Granulosa Cell Tumor. Am J Surg Pathol. 37(9),1450
  18. Hoang LN, McConechy MK, Köbel M, Han G, Rouzbahman M, Davidson B, Irving J, Ali RH, Leung S, McAlpine JN, Oliva E, Nucci MR, Soslow RA, Huntsman DG, Gilks CB, Lee CH. (2013-09-01). Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. Am J Surg Pathol. 37(9),1421
  19. Koebel M, Kalloger S, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GA, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich KB, Edwards RP, Modugno F, Bunker CH, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks B, Huntsman DG, Ramus SJ, Goode EL. (2013-07-23). Biomarker-based ovarian carcinoma typing: a histological investigation in the Ovarian Tumor Tissue Analysis consortium. Cancer Epidemiol Biomarkers Prev. 22(10),1677
  20. Sieh W, Köbel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ. (2013-07-08). Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 14(9),853
  21. Miller DM, McAlpine JN, Gilks CB, Huntsman DG. (2013-06-01). Opportunistic salpingectomy: the way forward-response to Steven Narod. Curr Oncol. 20(3),143
  22. Lichner Z, Scorilas A, White NM, Girgis AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D, Yousef GM. (2013-04-01). The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma. Am J Pathol. 182(4),1163
  23. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M; PRACTICAL Consortium, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Ling Woo Y, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Palmieri Weber R, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Anne Rossing M, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Zawiah Omar S, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Mat Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubiński J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Krüger Kjaer S, Kiemeney LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall CK, Høgdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Dürst M, du Bois A, Dörk T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA; stralian Ovarian Cancer Study Group; stralian Cancer Study, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Leigh Pearce C. (2013-03-27). Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 4(0),1628
  24. Gamwell LF, Gambaro K, Merziotis M, Crane C, Arcand SL, Bourada V, Davis C, Squire JA, Huntsman DG, Tonin PN, Vanderhyden BC. (2013-02-21). Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet J Rare Dis. 8(1),33
  25. Anglesio M, Wang Y, Yang W, Senz J, Wan A, Heravi-Moussavi A, Salamanca C, Maines-Bandiera S, Huntsman D, Morin G. (2013-02-01). Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. J Pathol. 229(3),400
  26. Kommoss S, Anglesio MS, Mackenzie R, Yang W, Senz J, Ho J, Bell L, Lee S, Lorette J, Huntsman DG, Blake Gilks C. (2013-01-25). FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Mod Pathol. 26(6),860
  27. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Köbel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M. (2013-01-02). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 123(1),517
  28. Bashashati A, Haffari G, Ding J, Ha G, Lui K, Rosner J, Huntsman DG, Caldas C, Aparicio SA, Shah SP. (2012-12-22). DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biol. 13(12),124
  29. D'Angelo E, Ali RH, Espinosa I, Lee CH, Huntsman DG, Gilks B, Prat J. (2012-12-01). Endometrial Stromal Sarcomas With Sex Cord Differentiation Are Associated With PHF1 Rearrangement. Am J Surg Pathol. 37(4),514
  30. Tone A, McAlpine J, Finlayson S, Gilks CB, Heywood M, Huntsman D, Miller D. (2012-12-01). It sounded like a good idea at the time. J Obstet Gynaecol Can. 34(12),1127
  31. Isphording A, Ali RH, Irving J, Goytain A, Nelnyk N, Hoang LN, Gilks CB, Huntsman DG, Nielsen TO, Nucci MR, Lee CH. (2012-11-15). YWHAE-FAM22 endometrial stromal sarcoma: diagnosis by reverse transcription-polymerase chain reaction in formalin-fixed, paraffin embedded tumor. Hum Pathol. 44(5),837
  32. Lee CH, Ali RH, Rouzbahman M, Marino-Enriquez A, Zhu M, Guo X, Brunner AL, Chiang S, Leung S, Nelnyk N, Huntsman DG, Blake Gilks C, Nielsen TO, Dal Cin P, van de Rijn M, Oliva E, Fletcher JA, Nucci MR. (2012-10-01). Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 36(10),1562
  33. Spowart JE, Townsend KN, Huwait H, Eshragh S, West NR, Ries JN, Kalloger S, Anglesio M, Gorski SM, Watson PH, Gilks CB, Huntsman DG, Lum JJ. (2012-08-27). The Autophagy Protein LC3A Correlates with Hypoxia and is a Prognostic Marker of Patient Survival in Clear Cell Ovarian Cancer. J Pathol. 228(4),437
  34. Jakate K, Azimi F, Ali RH, Lee CH, Clarke BA, Rasty G, Shaw PA, Melnyk N, Huntsman DG, Laframboise S, Rouzbahman M. (2012-08-24). Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors. Mod Pathol. 26(1),95
  35. Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkäs K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, Bégin LR, van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD. (2012-08-21). PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 107(5),800
  36. Anglesio M, Kommoss S, Tolcher M, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff B, Kalloger S, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia J, Schoolmeester J, Bakkum-Gamez J, Tinker A, Bowtell D, Huntsman D, Gilks C, McAlpine J. (2012-08-16). Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 229(1),111
  37. Crisan A, Goya R, Ha G, Ding J, Prentice LM, Oloumi A, Senz J, Zeng T, Tse K, Delaney A, Marra MA, Huntsman DG, Hirst M, Aparicio S, Shah S. (2012-08-16). Mutation discovery in regions of segmental cancer genome amplifications with CoNAn-SNV: a mixture model for next generation sequencing of tumors. PLoS One. 7(8),41551
  38. Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, Gilks CB, McAlpine JN. (2012-08-01). Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. 120(2),235
  39. McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. (2012-05-31). Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 228(1),20
  40. Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J, Hoskins PJ, Stuart GC, Swenerton KD, Huntsman DG, Gilks CB, Miller DM, McAlpine JN. (2012-05-01). The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol. 10(5),296
  41. Tone AA, Huntsman DG, Miller DM. (2012-04-01). Screening of symptomatic women for ovarian cancer. Lancet Oncol. 13(4),137
  42. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A (2012-04-01). Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 13(4),385
  43. Oliveira P, Sanges R, Huntsman D, Stupka E, Oliveira C. (2012-02-08). Characterization of the intronic portion of cadherin superfamily members, common cancer orchestrators. Eur J Hum Genet. 20(8),878
  44. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S. (2012-02-01). FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat. 131(3),881
  45. McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB. (2012-01-27). BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 25(5),740
  46. Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan AN, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee CH, Zhao C, Young RH, Aparicio SA, Sorensen PH, Woo MM, Boyd N, Jones SJ, Hirst M, Marra MA, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG. (2012-01-19). Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med. 366(3),234
  47. Lee CH, Ou WB, Mariño-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB, McAlpine JN, Gilks CB, Yaffe MB, Prentice LM, McPherson A, Jones SJ, Marra MA, Shah SP, van de Rijn M, Huntsman DG, Dal Cin P, Debiec-Rychter M, Nucci MR, Fletcher JA. (2012-01-17). 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A. 109(3),929
  48. Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A. (2012-01-01). Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer. 22(1),9
  49. Hunter SM, Anglesio MS, Sharma R, Gilks B, Melnyk N, Chiew YE, Longacre TA, Defazio A, Huntsman DG, Gorringe KL, Campbell IG. (2011-12-01). Copy number aberrations in benign serous ovarian tumors: a case for reclassification? Clin Cancer Res. 17(23),7273
  50. Turashvili G, Yang W, McKinney S, Kalloger S, Gale N, Ng Y, Chow K, Bell L, Lorette J, Carrier M, Luk M, Aparicio S, Huntsman D, Yip S. (2011-09-21). Nucleic acid quantity and quality from paraffin blocks: Defining optimal fixation, processing and DNA/RNA extraction techniques. Exp Mol Pathol. 92(1),33
  51. Schrader KA, Heravi-Moussavi A, Waters PJ, Senz J, Whelan J, Ha G, Eydoux P, Nielsen T, Gallagher B, Oloumi A, Boyd N, Fernandez BA, Young TL, Jones SJ, Hirst M, Shah SP, Marra MA, Green J, Huntsman DG. (2011-09-01). Using next-generation sequencing for the diagnosis of rare disorders: a family with retinitis pigmentosa and skeletal abnormalities. J Pathol. 255(1),12
  52. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. (2011-09-01). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12(9),852
  53. Chiang S, Ali R, Melnyk N, McAlpine JN, Huntsman DG, Gilks CB, Lee CH, Oliva E. (2011-09-01). Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol. 35(9),1364
  54. Collins IM, Domchek SM, Huntsman DG, Mitchell G. (2011-08-23). The tubal hypothesis of ovarian cancer: caution needed. Lancet Oncol. 12(12),1089
  55. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. (2011-07-06). Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 6(7),21121
  56. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis IL, Pritchard KI. (2011-07-01). Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat. 128(2),401
  57. Köbel M, Turbin D, Kalloger SE, Gao D, Huntsman DG, Gilks CB. (2011-07-01). Biomarker Expression in Pelvic High-grade Serous Carcinoma: Comparison of Ovarian and Omental Sites. Int J Gynecol Pathol. 30(4),366
  58. Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG. (2011-07-01). Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. 224(3),328
  59. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, Godwin AK, Gross J, Hartmann L, Huang M, Huntsman DG, Iacocca M, Imielinski M, Kalloger S, Karlan BY, Levine DA, Mills GB, Morrison C, Mutch D, Olvera N, Orsulic S, Park K, Petrelli N, Rabeno B, Rader JS, Sikic BI, Smith-McCune K, Sood AK, Bowtell D, Penny R, Testa JR, Chang K, Dinh HH, Drummond JA, Fowler G, Gunaratne P, Hawes AC, Kovar CL, Lewis LR, Morgan MB, Newsham IF, Santibanez J, Reid JG, Trevino LR, Wu YQ, Wang M, Muzny DM, Wheeler DA, Gibbs RA, Getz G, Lawrence MS, Cibulskis K, Sivachenko AY, Sougnez C, Voet D, Wilkinson J, Bloom T, Ardlie K, Fennell T, Baldwin J, Gabriel S, Lander ES, Ding LL, Fulton RS, Koboldt DC, McLellan MD, Wylie T, Walker J, O'Laughlin M, Dooling DJ, Fulton L, Abbott R, Dees ND, Zhang Q, Kandoth C, Wendl M, Schierding W, Shen D, Harris CC, Schmidt H, Kalicki J, Delehaunty KD, Fronick CC, Demeter R, Cook L, Wallis JW, Lin L, Magrini VJ, Hodges JS, Eldred JM, Smith SM, Pohl CS, Vandin F, Raphael BJ, Weinstock GM, Mardis ER, Wilson RK, Meyerson M, Winckler W, Getz G, Verhaak RG, Carter SL, Mermel CH, Saksena G, Nguyen H, Onofrio RC, Lawrence MS, Hubbard D, Gupta S, Crenshaw A, Ramos AH, Ardlie K, Chin L, Protopopov A, Zhang J, Kim TM, Perna I, Xiao Y, Zhang H, Ren G, Sathiamoorthy N, Park RW, Lee E, Park PJ, Kucherlapati R, Absher M, Waite L, Sherlock G, Brooks JD, Li JZ, Xu J, Myers RM, Laird W, Cope L, Herman JG, Shen H, Weisenberger DJ, Noushmehr H, Pan F, Triche T Jr, Berman BP, Van Den Berg DJ, Buckley J, Baylin SB, Spellman PT, Purdom E, Neuvial P, Bengtsson H, Jakkula LR, Durinck S, Han J, Dorton S, Marr H, Choi YG, Wang V, Wang NJ, Ngai J, Conboy JG, Parvin B, Feiler HS, Speed TP, Gray JW, Levine A, Socci ND, Liang Y, Taylor BS, Schultz N, Borsu L, Lash AE, Brennan C, Viale A, Sander C, Ladanyi M, Hoadley KA, Meng S, Du Y, Shi Y, Li L, Turman YJ, Zang D, Helms EB, Balu S, Zhou X, Wu J, Topal MD, Hayes DN, Perou CM, Getz G, Voet D, Saksena G, Zhang J, Zhang H, Wu CJ, Shukla S, Cibulskis K, Lawrence MS, Sivachenko A, Jing R, Park RW, Liu Y, Park PJ, Noble M, Chin L, Carter H, Kim D, Karchin R, Spellman PT, Purdom E, Neuvial P, Bengtsson H, Durinck S, Han J, Korkola JE, Heiser LM, Cho RJ, Hu Z, Parvin B, Speed TP, Gray JW, Schultz N, Cerami E, Taylor BS, Olshen A, Reva B, Antipin Y, Shen R, Mankoo P, Sheridan R, Ciriello G, Chang WK, Bernanke JA, Borsu L, Levine DA, Ladanyi M, Sander C, Haussler D, Benz CC, Stuart JM, Benz SC, Sanborn JZ, Vaske CJ, Zhu J, Szeto C, Scott GK, Yau C, Hoadley KA, Du Y, Balu S, Hayes DN, Perou CM, Wilkerson MD, Zhang N, Akbani R, Baggerly KA, Yung WK, Mills GB, Weinstein JN, Penny R, Shelton T, Grimm D, Hatfield M, Morris S, Yena P, Rhodes P, Sherman M, Paulauskis J, Millis S, Kahn A, Greene JM, Sfeir R, Jensen MA, Chen J, Whitmore J, Alonso S, Jordan J, Chu A, Zhang J, Barker A, Compton C, Eley G, Ferguson M, Fielding P, Gerhard DS, Myles R, Schaefer C, Mills Shaw KR, Vaught J, Vockley JB, Good PJ, Guyer MS, Ozenberger B, Peterson J, Thomson E. (2011-06-29). Integrated genomic analyses of ovarian carcinoma. Nature. 474(7353),609
  60. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, Griffith M, Heravi Moussavi A, Senz J, Melnyk N, Pacheco M, Marra MA, Hirst M, Nielsen TO, Sahinalp SC, Huntsman D, Shah SP. (2011-05-19). deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data. PLoS Comput Biol. 7(5),1001138
  61. Prentice LM, d'Anglemont de Tassigny X, McKinney S, Ruiz de Algara T, Yap D, Turashvili G, Poon S, Sutcliffe M, Allard P, Burleigh A, Fee J, Huntsman DG, Colledge WH, Aparicio SA. (2011-04-28). The testosterone-dependent and independent transcriptional networks in the hypothalamus of Gpr54 and Kiss1 knockout male mice are not fully equivalent. BMC Genomics. 12(1),209
  62. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ; Australian Ovarian Cancer Study Group, Pearson RB, B√łrresen-Dale AL, Huntsman DG, Defazio A, Creighton CJ, Smyth GK, Bowtell DD. (2011-04-13). Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. PLoS One. 6(4),18064
  63. Al-Agha OM, Huwait HF, Chow C, Yang W, Senz J, Kalloger SE, Huntsman DG, Young RH, Gilks CB. (2011-04-01). FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary. Am J Surg Pathol. 35(4),484
  64. Terry J, De Luca A, Leung S, Peacock G, Wang Y, Elliot WM, Huntsman D. (2011-04-01). Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and nonsquamous subtypes. Arch Pathol Lab Med. 135(4),433
  65. Lou Y, McDonald PC, Oloumi A, Chia SK, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman DG, Clarke B, Sutherland BW, Waterhouse D, Bally MB, Roskelley CD, Overall CM, Minchinton A, Pacchiano F, Carta F, Scozzafava A, Touisni N, Winum JY, Supuran CT, Dedhar S. (2011-03-17). Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. Cancer Res. 71(9),3364
  66. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD. (2011-03-17). MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 471(7338),377
  67. McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, Heravi-Moussavi A, Morin GB, Mes-Masson AM; Australian Ovarian Cancer Study Group, Carey MS, McAlpine JN, Kwon JS, Prentice LM, Boyd N, Shah SP, Gilks CB, Huntsman DG. (2011-03-07). Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol. 223(5),567
  68. Anglesio MS, George J, Kulbe H, Friedlander ML, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Group AO, Okamoto A, Birrer MJ, Huntsman DG, Defazio A, Kalloger SE, Balkwill FR, Gilks B, Bowtell DD. (2011-02-22). IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clin Cancer Res. 17(8),2538
  69. Anglesio MS, Carey MS, Köbel M, Mackay H, Huntsman DG. (2011-01-26). Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol. 121(2),407
  70. Ali AM, Dawson SJ, Blows FM, Provenzano E, Ellis IO, Baglietto L, Huntsman D, Caldas C, Pharoah PD. (2011-01-25). Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. Br J Cancer. 104(4),693
  71. McAlpine JN, El Hallani S, Lam SF, Kalloger SE, Luk M, Huntsman DG, Macaulay C, Gilks CB, Miller DM, Lane PM. (2011-01-14). Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: A promising step towards screening and early detection. Gynecol Oncol. 120(3),385
  72. Kalloger SE, Köbel M, Leung S, Mehl E, Gao D, Marcon KM, Chow C, Clarke BA, Huntsman DG, Gilks CB. (2010-12-03). Calculator for ovarian carcinoma subtype prediction. Mod Pathol. 24(4),512
  73. Kortmann UK, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston A, O'Connor MJ, Huntsman DG, Wang Y, Gilks B. (2010-11-19). Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res. 17(4),783
  74. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG. (2010-10-14). ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 363(16),1532
  75. Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, Isaacs C, Brown P, Balmana J, Razzak AR, Miron P, Coffey K, Terry MB, John EM, Andrulis IL, Knight JA, O'Malley FP, Daly M, Bender P; kConFab, Moore R, Southey MC, Hopper JL, Garber JE, Huntsman DG. (2010-10-04). Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 48(1),64
  76. Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, Los G, Rejto PA, Aparicio SA. (2010-09-17). P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Mod Pathol. 24(1),64
  77. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, Callagy G, Green AR, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P. (2010-07-27). BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 103(5),668
  78. Köbel M, Reuss A, Bois AD, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB. (2010-07-13). The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 222(2),191
  79. Gilks CB, Huntsman DG. (2010-07-01). Diagnostic Uncertainty in the Interpretation of Small Atypical Acinar Lesions of Prostate. Am J Surg Pathol. 34(7),1071
  80. Köbel M, Kalloger SE, Baker PM, Ewanowich CA, Arseneau J, Zherebitskiy V, Abdulkarim S, Leung S, Duggan MA, Fontaine D, Parker R, Huntsman DG, Gilks CB. (2010-07-01). Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol. 34(7),984
  81. Cooke SL, Ng CK, Melnyk N, Garcia MJ, Hardcastle T, Temple J, Langdon S, Huntsman D, Brenton JD. (2010-06-28). Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene. 29(35),4905
  82. Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG, Wiseman SM. (2010-06-01). HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg. 251(6),1107
  83. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MWR, Provenzano E, Dawson S, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D (2010-05-27). Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies PLoS Med. 7(5),0
  84. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. (2010-05-15). Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res. 16(10),2852
  85. Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB. (2010-05-01). Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 29(3),203
  86. Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS, Owen DA. (2010-02-23). Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer. 10(1),59
  87. Goya R, Sun MG, Morin RD, Leung G, Ha G, Wiegand KC, Senz J, Crisan A, Marra MA, Hirst M, Huntsman D, Murphy KP, Aparicio S, Shah SP. (2010-02-03). SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics. 26(6),730
  88. Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM. (2010-02-01). Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol. 220(3),392
  89. Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW Jr, Badve S. (2010-01-23). Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Res Treat. 124(2),327
  90. Sun Y, Turbin D, Ling K, Thapa N, Leung S, Huntsman D, Anderson RA. (2010-01-14). Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer. Breast Cancer Res Treat. 12(1),6
  91. Falconer E, Chavez EA, Henderson A, Poon SS, McKinney S, Brown L, Huntsman DG, Lansdorp PM. (2010-01-07). Identification of sister chromatids by DNA template strand sequences. Nature. 463(7277),93
  92. Köbel M, Gilks CB, Huntsman DG. (2009-12-15). Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res. 69(24),9160
  93. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM. (2009-12-10). HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 9(0),433
  94. Schrader KA, Gorbatcheva B, Senz J, Heravi-Moussavi A, Melnyk N, Salamanca C, Maines-Bandiera S, Cooke SL, Leung P, Brenton JD, Gilks CB, Monahan J, Huntsman DG. (2009-11-24). The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors. PLoS One. 4(11),7988
  95. Aparicio SA, Huntsman DG. (2009-11-17). Does massively parallel DNA resequencing signify the end of histopathology as we know it? J Pathol. 220(2),307
  96. Watson PH, Wilson-McManus JE, Barnes RO, Giesz SC, Png A, Hegele RG, Brinkman JN, Mackenzie IR, Huntsman DG, Junker A, Gilks B, Skarsgard E, Burgess M, Aparicio S, McManus BM. (2009-11-12). Evolutionary concepts in biobanking - the BC BioLibrary. J Transl Med. 7(0),95
  97. Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J, Langerød A, Han W, Noh DY, Jeffrey SS, Huntsman DG, Børresen-Dale AL, Pollack JR. (2009-11-02). Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene. 29(5),774
  98. KŲbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. (2009-10-10). Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecol Oncol. 116(1),50
  99. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. (2009-10-08). Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 461(7265),809
  100. Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB. (2009-10-02). MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One. 4(10),7314
  101. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. (2009-09-20). Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 27(27),4536
  102. Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, Huntsman DG. (2009-07-28). Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Breast Cancer Res Treat. 121(2),347
  103. Shah SP, Koebel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. (2009-06-10). Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 360(26),2719
  104. Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, Carrier M, Huntsman D, Aparicio S. (2009-05-29). Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer. 9(0),165
  105. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA Jr, Watson MA, Saporita A, Weber JD, Ellis MJ. (2009-04-14). PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 69(9),3955
  106. Köbel M, Gilks CB, Huntsman DG. (2009-03-12). Dicer and Drosha in ovarian cancer. N Engl J Med. 360(11),1150
  107. Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D. (2009-02-01). The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 19(1),58
  108. Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB. (2009-01-09). IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 22(3),469
  109. Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB. (2009-01-01). A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. Am J Surg Pathol. 33(1),14
  110. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB. (2008-12-05). Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 22(3),393
  111. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. (2008-12-02). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5(12),232
  112. Thorat MA, Turbin D, Morimiya A, Leung S, Zhang Q, Jeng MH, Huntsman DG, Nakshatri H, Badve S. (2008-12-01). Amplified in breast cancer 1 expression in breast cancer. Histopathology 53(6),634
  113. Schrader KA, Nelson TN, De Luca A, Huntsman DG, McGillivray BC. (2008-11-27). Multiple granular cell tumors are an associated feature of LEOPARD syndrome caused by mutation in PTPN11. Clin Genet. 75(2),185
  114. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K. (2008-11-10). Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. J Clin Oncol. 26(35),5697
  115. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE. (2008-10-16). Re-defining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 10(5),86
  116. Bergamaschi A, Kim YH, Kwei KA, La Choi Y, Bocanegra M, Langer√łd A, Han W, Noh DY, Huntsman DG, Jeffrey SS, B√łrresen-Dale AL, Pollack JR. (2008-10-02). CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer. Mol Oncol. 2(4),327
  117. Wong MP, Cheang M, Yorida E, Coldman A, Gilks CB, Huntsman D, Berean K. (2008-10-01). Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. Pathology. 40(6),611
  118. Giltnane JM, Molinaro A, Cheng H, Robinson A, Turbin D, Gelmon K, Huntsman D, Rimm DL. (2008-10-01). Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med. 132(10),1635
  119. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. (2008-09-01). Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 110(3),408
  120. Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, Köbel M. (2008-09-01). Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 10(9),1021
  121. FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG. (2008-08-11). Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 8(0),230
  122. Köbel M, Huntsman D, Gilks CB. (2008-08-01). Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med. 22(0),10
  123. Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, Chin K, Teschendorff AE, Quackenbush JF, Marioni JC, Leung S, Perou CM, Neilsen TO, Ellis M, Gray JW, Bernard PS, Huntsman DG, Caldas C. (2008-07-01). ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet. 40(7),806
  124. Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM, Huntsman DG, Gilks CB, McAlpine JN, Wang YZ. (2008-06-10). Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol. 110(2),256
  125. Brown LA, Kalloger SE, Miller MA, Shih IeM, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG. (2008-06-01). Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer. 47(6),481
  126. Crabb SJ, Cheang MC, Leung S, Immonen T, Nielsen TO, Huntsman DD, Bajdik CD, Chia SK. (2008-06-01). Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 8(3),249
  127. Woo MM, Salamanca CM, Miller M, Symowicz J, Leung PC, Oliveira C, Ehlen TG, Gilks CB, Huntsman D, Auersperg N. (2008-01-23). Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas. Int J Gynecol Cancer. 18(6),1234
  128. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG. (2008-01-22). Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 8(17),0
  129. Crabb SJ, Bajdik CD, Leung S, Speers CH, Kennecke H, Huntsman DG, Gelmon KA. (2008-01-14). Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res. 10(1),6
  130. Jensen KC, Turbin DA, Leung S, Miller MA, Johnson K, Norris B, Hastie T, McKinney S, Nielsen TO, Huntsman DG, Gilks CB, West RB. (2008-01-09). New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat. 112(3),453
  131. Fadlelmola FM, Zhou M, de Leeuw RJ, Dosanjh NS, Harmer K, Huntsman D, Lam WL, Banerjee D. (2008-01-07). Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines. Mol Cancer. 7(2),0
  132. Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB. (2008-01-01). Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK). Mol Cancer Ther. 7(1),59
  133. Pinke DE, Kalloger SE, Francetic T, Huntsman DG, Lee JM. (2007-12-28). The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol Oncol. 108(3),561
  134. Hewitt J, Craven SJ, Brown LA, Bleackley MR, Ballard JN, Smith VC, Ofosu FA, Huntsman DG, Wadsworth LD, Wu JK, Macgillivray RT. (2007-12-19). Molecular determination of the breakpoints of a 161 556 bp deletion at chromosome 13q34 that presented as severe factor VII deficiency in a neonate. Br J Haematol. 140(5),589
  135. Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL. (2007-12-01). Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its ... J Clin Oncol. 25(34),5418
  136. Bajdik CD, Sung S, Spinelli JJ, Huntsman D, Gallinger S, Horsman D, Gallagher RP. (2007-12-01). Predicting the performance of a genetic testing service for cancer susceptibility. Genet Test. 11(4),381
  137. Intaraprasong P, Assi K, Owen DA, Huntsman DG, Chung SW, Scudamore CH, Yoshida EM, Salh B. (2007-12-01). Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. Anticancer Res. 27(6),4371
  138. Prentice LM, Klausen C, Kalloger S, Kobel M, McKinney S, Santos JL, Kenney C, Mehl E, Gilks CB, Leung P, Swenerton K, Huntsman DG, Aparicio SA. (2007-11-15). Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med. 5(1),33
  139. Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, Gown AM, van de Rijn M, Nielsen TO, Gilks CB, Huntsman DG. (2007-10-03). Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 110(3),417
  140. Savage K, Leung S, Todd SK, Brown LA, Jones RL, Robertson D, James M, Parry S, Rodrigues Pinilla SM, Huntsman D, Reis-Filho JS. (2007-10-03). Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat. 110(2),245
  141. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, Mills GB, Huntsman DG, Gray JW. (2007-10-01). Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer. Clin Cancer Res. 13(19),5745
  142. Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D, Parker R, Gilks CB. (2007-08-24). Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol. 20(11),1156
  143. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H. (2007-08-01). FOXA1 Expression in Breast Cancer Correlation with Luminal Subtype A and Survival. Clin Cancer Res. 13(15),4415
  144. Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE, Huntsman D. (2007-07-27). Germline E-Cadherin mutations in familial lobular breast cancer. J Med Genet. 44(11),726
  145. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD. (2007-07-24). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 7(1),134
  146. Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, Lavoie C, Turpin J, Cianflone K, Huntsman DG, Muller WJ. (2007-07-16). Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development. Mol Cell Biol. 27(18),6361
  147. Conklin C, Huntsman D, Yorida E, Makretsov N, Turbin D, Bechberger JF, Sin WC, Naus CC. (2007-06-20). Tissue microarray analysis of connexin expression and its prognostic significance in human breast cancer. Cancer Lett. 255(2),284
  148. Cupp JS, Miller MA, Montgomery KD, Nielsen TO, Oʼconnell JX, Huntsman D, Rijn MV, Gilks CB, West RB. (2007-06-01). Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive Synovitides. Am J Surg Pathol. 31(6),970
  149. Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG. (2007-03-13). Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 107(2),249
  150. Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, Pollack JR. (2007-03-02). A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol. 20(4),467
  151. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B. (2007-02-01). Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 14(2),719
  152. Ling K, Bairstow SF, Carbonara C, Turbin DA, Huntsman DG, Anderson RA. (2007-01-29). Type I{gamma} phosphatidylinositol phosphate kinase modulates adherens junction and E-cadherin trafficking via a direct interaction with {micro}1B adaptin. J Cell Biol. 176(3),343
  153. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG. (2007-01-26). Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol. 60(11),1238
  154. Brown LA, Huntsman D. (2007-01-10). Fluorescent in situ hybridization on tissue microarrays: challenges and solutions. J Mol Histol. 38(2),151
  155. Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM. (2006-12-20). Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. J Clin Oncol. 24(36),5637
  156. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. (2006-11-24). Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol. 20(1),84
  157. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Zhang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. (2006-09-01). Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6),455
  158. Kulkarni G, Turbin DA, Amiri A, Jeganathan S, Andrade-Navarro MA, Wu TD, Huntsman DG, Lee JM. (2006-08-09). Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat. 102(1),31
  159. Robinson AG, Turbin D, Thomson T, Yorida E, Ellard S, Bajdik C, Huntsman D, Gelmon K. (2006-08-01). Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer. 7(3),254
  160. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B. (2006-05-01). Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg. 191(5),581
  161. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C. (2006-04-15). Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index Clin Cancer Res. 12(8),2468
  162. West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, Goldblum JR, Corless CL, Brown PO, Gilks CB, Nielsen TO, Huntsman D, van de Rijn M. (2006-01-17). A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 103(3),690
  163. Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. (2006-01-01). MDM2 protein expression is a negative prognostic marker in breast carcinoma. Modern Pathology 19(1),69
  164. So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. (2005-12-01). Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther. 4(12),1837
  165. Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, Diez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkila P, Lerma E, Kallioniemi A, Rivas C, Foulkes WD, Nevanlinna H, Benitez J. (2005-10-20). Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol. 23(30),7503
  166. Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D. (2005-10-19). Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecologic Oncology 100(2),264
  167. Feng Q, Li P, Salamanca C, Huntsman D, Leung PC, Auersperg N. (2005-10-01). Caspase-1alpha is down-regulated in human ovarian cancer cells and the overexpression of caspase-1alpha induces apoptosis. Cancer Res. 65(19),8591
  168. Raouf A, Brown L, Vrcelj N, To K, Kwok W, Huntsman D, Eaves CJ. (2005-09-07). Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst. 97(17),1302
  169. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE. (2005-08-01). Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 7(5),796
  170. Prentice LM, Shadeo A, Lestou VS, Miller MA, Deleeuw RJ, Makretsov N, Turbin D, Brown LA, Macpherson N, Yorida E, Cheang MC, Bentley J, Chia S, Nielsen TO, Gilks CB, Lam W, Huntsman DG. (2005-07-18). NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene. 24(49),7281
  171. Kelley TW, Huntsman D, McNagny KM, Roskelley CD, Hsi ED. (2005-07-01). Podocalyxin : A Marker of Blasts in Acute Leukemia Am J Clin Pathol. 124(1),134
  172. Arce C, Cortes-Padilla D, Huntsman DG, Miller MA, Duennas-Gonzalez A, Alvarado A, Perez V, Gallardo-Rincon D, Lara-Medina F. (2005-06-17). Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature. World J Surg Oncol. 3(1),35
  173. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. (2005-06-16). Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 24(26),4281
  174. Terry J, Barry TS, Horsman DE, Hsu FD, Gown AM, Huntsman DG, Nielsen TO. (2005-06-01). Fluorescence In Situ Hybridization for the Detection of t(X;18)(p11.2;q11.2) in a Synovial Sarcoma Tissue Microarray Using a Breakapart-Style Probe. Diagn Mol Pathol. 14(2),77
  175. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. (2005-05-01). Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103(9),1770
  176. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V, Li G. (2005-05-01). Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 124(5),1044
  177. Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB. (2005-04-01). Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol. 24(2),147
  178. Suriano G, Vrcelj N, Senz J, Ferreira P, Masoudi H, Cox K, Nabais S, Lopes C, Machado JC, Seruca R, Carneiro F, Huntsman DG. (2005-03-01). beta-Catenin (CTNNB1) gene amplification: A new mechanism of protein overexpression in cancer. Genes, Chromosomes and Cancer 42(3),238
  179. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. (2004-10-28). Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncology 96(1),48
  180. Au NHC, Gown A, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL. (2004-09-01). p63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 12(3),240
  181. Au NHC, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliot WM, Bebb G, Flint J, English J, Gilks CB, Grimes HL. (2004-09-01). Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers J of Pathology (UK) 204(1),101
  182. Somasiri A, Nielsen J, Makretsov N, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, and Roskelley CD. (2004-08-01). Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression Cancer Research 64(15),5068
  183. Makretsov N, Huntsman D, Nielsen T, Yorida E, Peacock M, Cheang M, Sandra E.Dunn, Hayes M, Matt van de Rijn, Bajdik C, and Gilks B. (2004-08-01). Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Cancer Clinical Cancer Research 10(18),6143
  184. Dabiri SH, Huntsman DG, Makretsov N, Cheang M, Gilks CB, Bajdik C, Gelmon KA, Chia S, Hayes MM. (2004-06-15). The presence of stromal mast cells identifies a subset of invasive breast cancers with a favourable prognosis. Mod Pathol 17(6),690
  185. Makretsov N, He M, Hayes M, Chia S, Horsman DE, Sorensen PH, and Huntsman D. (2004-06-01). A fluorescence in-situ hybridisation study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 40(2),152
  186. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. (2004-04-01). Interpretation of p53 immunohistochemical staining in endometrial carcinoma: establishing a clinically relevant cut-off. Int J Gynecol Pathol 23(2),129
  187. Maines-Bandiera SL, Huntsman D, Lestou VS, Kuo WL, Leung PC, Horsman RD, Wong AS, Woo MM, Choi KK, Roskelley CD, Auersperg N. (2004-04-01). Epithelio-mesenchymal transition in a neoplastic ovarian epithelial hybrid cell line. Differentiation. 72(4),150
  188. Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB,Makretsov N, Bajdik CD, Brookes C, Neckers LM, Evdokimova V, Huntsman DG, Dunn SE (2004-01-01). Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival Cancer Research 64(1),286
  189. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin S-F, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Yu DS, Vnkitaraman A, Ponder B, Doherty A, Aparicio S, (2003-11-26). EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115(5),523
  190. Makretsov N, Gilks CB, Coldman AJ, Hayes M, and Huntsman D. (2003-10-15). Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol 34(10),1001
  191. Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D, Martinka M, and Li G. (2003-10-01). Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 9(0),4409
  192. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D. (2003-09-01). Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol. 64(3),271
  193. Bamforth F, Brown L, Senz J, Huntsman D. (2003-07-01). Mechanisms of monozygotic (MZ) twinning: a possible role for the cell adhesion molecule, E-cadherin. Am J Med Genet A. 120(1),59
  194. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, van de Rijn M, Gilks CB. (2002-12-15). Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 15(12),1374
  195. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F, MacPherson N, Horsman D, Poremba C, Sorensen PH. (2002-11-01). Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2(5),367
  196. Mattman A, Huntsman D, Lockitch G, Langlois S, Buskard N, Ralston D, Butterfield Y, Rodrigues P, Jones S, Porto G, Marra M, De Sousa M, Vatcher G. (2002-08-01). Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood. 100(3),1075
  197. Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, and Gilks CB. (2002-03-01). Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 117(0),723
Invited Presentations
  1. Ontario Institute for Cancer Research and National Cancer Institute of Canada, State of the Science and Technology of Circulating Tumour Cells as Biomarkers in Cancer Treatment Trials Workshop, Toronto ON, March 28, 2009. Presentation "Detection of genetic abnormalities in CTCs".
  2. University of Chicago Pritzker School of Medicine, Breast Cancer Family Registry: 2nd Scientific Conference on Familial Aspects of Breast Cancer, San Antonio TX, December 10, 2008. Presentation "The role of CDH1 in breast cancer susceptibility"
  3. London Regional Cancer Program Translational Breast Cancer Research Unit and the CIHR Strategic Training Program in Cancer Research and Technology Transfer - CIHR Strategic Training Program and the Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit Seminar Series - Invited Speaker, London ON, November 27, 2008. Presentation "Hereditary diffuse gastric cancer: from the bench through families to the population"
  4. Hereditary Diffuse Gastric Cancer Workshop, International Gastric Cancer Linkage Consortium, Cancer Research UK Cambridge Research Institute, British Society of Gastroenterology, Cambridge, UK, November 20-21, 2008. Presentation
  5. University of British Columbia, Medical Undergraduate Society Research Forum, Vancouver, BC, November 06, 2008. Presentation
  6. Canadian Cancer Research Alliance/International Cancer Genome Consortium, Scientific Workshop, Toronto, ON, October 28, 2008. Presentation on Western Canada's ovarian cancer tumour inventory
  7. American College of Surgeons 94th Annual Clinical Congress, San Francisco, USA, October 14, 2008. Presentation "Hereditary diffuse gastric cancer"
  8. National Cancer Research Institute Cancer Conference, Birmingham, UK, October 05-08, 2008. Presentation "Ovarian carcinoma subtypes are different diseases: lesson from biomarker studies"
  9. Macgregor Lecturer, University of Alberta, Dept of Laboratory Medicine and Pathology, Presentation "From cancer susceptibility to next generation sequencing: the evolving role of oncopathology in the post genomic era: my research in CTC's, ovarian cancer genomics and hereditary cancer in a broader context"
  10. Familial Cancer: Research and Practice: Combined meeting of kConFab, The Australian Ovarian Cancer Study & the Family Cancer Clinics of Australia and New Zealand, Couran Cove Island, AU, August 19-22, 2008. Presentations "Hereditary diffuse gastric cancer and Ovarian carcinoma subtypes are different diseases"
  11. 4th PacRim Breast & Prostate Cancer Conference, August 12-16, 2008. Co-Chair of Session "Biomarkers and patient care - will they tell us who, when and how to treat?"
  12. Ovarian Cancer Conference, Rhodes, Greece, June 26-July 01, 2008. Presentation "Ovarian carcinomas are different subtypes: lessons from biomarker studies"
  13. Cancer Research Institute of the University of Montreal, Montreal, QC, May 07, 2008. Seminar "If ovarian cancer subtypes are different diseases, how does this change ovarian cancer research?"
  14. 4th Annual Canary Foundation Symposium, Stanford University CA, May 20-22, 2008.
  15. Ovarian Cancer Research Trainee Symposium, Montreal, QC, May 03, 2008. Presentation "Anatomy, cell biology and pathology"
  16. CBCRA Reasons for Hope Conference, Vancouver, BC, April 25-27, 2008. Plenary session "Molecular oncology, the baby and the bathwater: an introduction", Oral Presentation "Carbonic Anhydrase IX (CA IX) is a Predictive Marker for Benefit from Post-mastectomy Adjuvant Locoregional Radiation (RT): Results from the British Columbia Randomized Radiation Trial", and Ask the Experts Breakfast Panel
  17. University of Sherbrooke, Functional Genomics Laboratory, Sherbrooke, QC, April 16, 2008. "Hereditary diffuse gastric cancer: genetics, pathology and clinical management"
  18. Genomics Institute of the Norvatis Research Foundation, Oncology Board Meeting, San Diego, CA, April 09, 2008. "FISH: Search for Translocated Kinases"
  19. "Hereditary diffuse gastric cancer: genetics, pathology and clinical management"
  20. Genetics Rounds, Alberta Children's Hospital, Calgary, AB, January 23, 2008
  21. "Ovarian Carcinomas: different diseases not subtypes - setting the stage to f a new paradigm for ovarian cancer management"
  22. Tom Baker Cancer Centre Grand Rounds, Calgary, AB, January 23, 2008.
  23. 7th Annual Scientific Meeting, University of Montreal, Dept. of Medical Genetics, Montreal QC, December 06, 2007. "Hereditary diffuse gastric cancer: genetics, pathology, and clinical management."
  24. BC Cancer Agency Annual Cancer Conference, Presentation "The Centre for Translational and Applied Genomics (CTAG): A molecular pathology platform for clinical development and research." Session chair: Predictive oncology & targeted therapeutics. Westin Bayshore, Vancouver, BC, November 29-December 01, 2007
  25. Toronto Ovarian Cancer Research Network, Princess Margaret Hospital, Toronto ON, November 02, 2007. "Ovarian carcinoma subtypes are different diseases: implications for biomarker studies and management."
  26. Institute of Molecular Pathology and Immunology of the University of Porto, Porto Portugal, October 15-16, 2007. "Hereditary diffuse gastric cancer."
  27. Mount Sinai School of Medicine, New York City, NY, June 12, 2007.
  28. Surgical Grand Rounds, Memorial Sloan-Kettering Cancer Centre, New York City NY, June 11, 2007. "Hereditary diffuse gastric cancer: from genetics to management."
  29. 3rd Annual Canary Foundation Symposium, Stanford University CA, May 22-24, 2007.
  30. Toronto Cancer Stem Cell Workshop, April 17-18, 2008.
  31. The Tucson Symposium, Ventana Medical Systems. Tucson AZ. March 6-7, 2007.
  32. Distinguished Guest Speaker, RCPA Pathology Update, Sydney AU, March 03, 2007. "Hereditary diffuse gastric cancer: Pathology, molecular genetics and clinical management."
  33. RCPA Pathology Update 2007, Sydney Convention & Exhibition Centre. Sydney AU. March 3-4, 2007
  34. University of Melbourne, Dept. of Medicine, Royal Melbourne and Western Hospitals, Peter MacCallum Cancer Centre, Melbourne AU, March 01, 2007. "Hereditary diffuse gastric cancer: Pathology, molecular genetics and clinical management."
  35. Familial Cancer Unit, Dept of Genetic Medicine, Women's & Children's Hospital, North Adelaide AU, February 27, 2007. "Making genetic pathology generic: population based assessment of novel cancer biomarkers."
  36. Familial Cancer Unit, Dept of Genetic Medicine, Women's & Children's Hospital, North Adelaide AU, February 26, 2007. "Hereditary diffuse gastric cancer: Pathology, molecular genetics and clinical management."
  37. Women's & Children's Hospital, Familial Cancer Unit, Department of Genetic Medicine, Evening Presentation, North Adelaide. February 27, 2007
  38. Institute of Medical and Veterinary Sciences, Presentation to Clinicians, Pathologists, and Scientists. Adelaide AU. February 26, 2007
  39. Women's & Children's Hospital, Familial Cancer Unit, Department of Genetic Medicine, Grand Rounds, North Adelaide. February 26, 2007
  40. INSIGHT, Laboratory Services in Canada, the Need for Modernization, Latest Initiatives, Best Practices. Vancouver BC. December 5, 2006
  41. Memorial University of Newfoundland, Provincial Medical Genetics Program, Eastern Health, Health Sciences Centre, Grand Rounds. St. John's NFLD. July 14 & 17, 2006
  42. Guy's Hospital, Hedley Atkins Breast Unit, London UK, July 13, 2006
  43. Breakthrough Breast Cancer Research Centre, Institute for Cancer Research, London UK. June 12, 2006
  44. Bradfield Family Reunion. Las Vegas NV. May 26, 2006
  45. Canary Foundation Scientific Advisory Board. San Jose CA. May 23-25, 2006
  46. Novartis Canada, NEOCAN Investigator Meeting, Montreal PQ, May 6, 2006
  47. Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, Grand Rounds "Hereditary diffuse gastric cancer and the tissue array based development of novel IHC and FISH based cancer biomarkers: cancer genetics for individuals, families and populations". Boston MA. March 10, 2006
  48. GUTG Retreat Agenda 2006, Delta Sun Peaks Resort, Sun Peaks, BC "Recent Advances in Basic Research on Prostate Cancer Ė Fusion of TMPRSS2 and ETS Transcription Factor Genes in CaP". April 6 to 9, 2006
  49. Yale University, Pathology, Grand Rounds, New Haven CT "Hereditary diffuse gastric cancer and the tissue array†based assessment of novel IHC and FISH based cancer biomarkers: cancer genetics for individuals, families and populations". March 9, 2006.
  50. Grand Rounds at Stanford, March 2006
  51. BCCA Annual Cancer Conference 2005, Westin Bayshore Hotel, Vancouver "Hereditary Diffuse Gastric Cancer: The Genetic Based Management of an Extreme Risk Family Cancer Syndrome", November 04, 2005.
  52. Provincial Laboratory Coordinating Office, Pan Pacific Hotel, Vancouver "Translating Molecular Science into Improved Healthcare: Balancing Inevitable Hype with Realistic Hope", November 03, 05
  53. Russian Cancer Research Centre, Moscow, Russia "Genetic analysis of tissue microarrays" & "Hereditary gastric cancer", September 28-29, 2005.
  54. kConfab, Couran Cove Island, Australia "The use of tissue microarrays for the validation of putative breast and ovarian cancer biomarkers and the linkage of molecular phenotypes to epidemiological data." & "Hereditary Diffuse Gastric Cancer", August 30-September 03, 2005.
  55. Queensland Institute of Medical Research, Brisbane, Australia "The development, validation and delivery of cancer biomarkers", August 30, 2005.
  56. Meeting with Marsha Rivkin Centre, Seattle, to present findings on the MRC Pilot Study, June 7, 2005.
  57. Dalhousie University, Dalhousie, Halifax. "Bringing cancer genomics to the bedside: A Pathologist's perspective" & "Tissue Microarrays: from biomarker discovery to clinical application", May 17-20, 2005.
  58. MD Anderson, Houston, Texas. "Tissue Microarray: from the mapping of clinical cytogenetic abnormalities through the clinical delivery of breast cancer biomarkers", April 28-29, 2005.
  59. ASIP Annual Meeting, San Deigo. "TMA-based molecular morphology approaches to the study of human mammary carcinoma", April 2-6, 2005.
  60. USCAP Annual Meeting, San Antonio, Texas. "Use of Tissue microarrays for Clinical Assessment of Breast Cancer Biomarkers" & "Hereditary Diffuse Gastric Cancer: Genetics, Pathology and Management". February 26-March 2, 2005.
  61. 96th AACR Annual Meeting, Anaheim, California. (Abstract #1619 - EMSY overexpression in human mammary epithelial cells produces a genetically unstable phenotype that mimcs BRCA2 loss) April 16-19, 2005.
  62. University of Calgary: Heriditary Gastric Cancer: Pathology & Laboratory Medicine Rounds, January 13, 2005
  63. University of Calgary. (Grand Rounds) "Tissue Microarrays in Pathology Research", January 13, 2005.
  64. University of Alberta, Alberta. "Hereditary Gastric Cancer". November 11-13, 2004.
  65. UBC & University of Alberta Depts of Obstetrics & Gynecology Conf: Science & Beyond III., Cancer Genetics: A Three Course Meal, Banff, Alta., November 13, 2004
  66. Alberta Cancer Board's Annual Research Meeting, Banff, Alberta. "From gene array to tissue array: Linking markers to clinical outcomes", November o9-10, 2004.
  67. Roy Col Phys & Surg of Can: CSCI Joe Doupe Lecture, Ottawa, September 30,2004
  68. N Am Assoc Central Can Reg Ann Meeting: Linking tissue archives to cancer registries: Salt Lake City, June 8, 2004.
  69. 13th Annual Cancer Symposium: Molecular Changes in Gastric Cancer: Seoul, April 2004
  70. American Soc Clin Onc: GI Symposium: Hereditary Gastric Cancer: San Fran, January 2004.
  71. William Anderson lectureship: Tissue Microarray: More than a Biomarker Validation Tool: Toronto September 29, 2003.
  72. 2003 Medical Graduates' Society Reunion: How will the human Genome Project effect medical practice: the cancer story: Memorial University of Newfoundland: August 02, 2003.
  73. Cleveland Clinic: Can Tissue Microarrays Salvage Pathology?: Cleveland Ohio: June 16, 2003.
  74. Breast Intergroup Meeting: The BC Breast Cancer TMA Project and NCIC TMA based studies: Chicago, Illinois: June 25, 2003.
  75. International Gastric Cancer Linkage Consortium Meeting: "An update from Canada" Munich, Germany: May 23, 2003
  76. UBC Departments of Surgery Grand Rounds: Bringing Cancer Genomics to the Bedside: December 11, 2002.
  77. BCALP Annual meeting: Cancer Genetics an introduction for pathologists: November. 22, 2002.
  78. DA Boyes Society: Inherited Gynecologic Cancer a Review; Vancouver, November 08, 2002
  79. University of Toronto (Mt. Sinai Hosp): Visiting lectureship in Cancer Genetics, Nov. 25, 2002.
  80. BCCA Annual Research Meeting: Invited lecture (using IHC to Validate Genomic findings), Nov 30, 2002
  81. Pathology Update at Whistler: Cancer Genetics a Three Course Meal: August 07, 2002.
  82. International Gastric Cancer Linkage cocnsortium: New families and an Animal Model for HDGC: Oporto, Portugal, May 27, 2002
  83. GOC Annual meeting: Cancer Genetic Review, April 13, 2002.
  84. NICI Tissue Banking Group: Tissue Microarray Technology, April 14, 2002.
  85. "Early Gastric Cancer, Genetically susceptible individuals".
  86. United States and Canadian Academy of Pathology and Society for Pediatric Pathology, Chicago, Feb. 2002.
  87. BCCA Annual Cancer Research conference; Cell Signaling for Beginners (with G. Krystal), November 2001.
  88. World Cardiovascular Congress: DNA Chips: What Microarrays Can Tell Us. July 09, 2001.
  89. International Gastric Cancer Linkage Consortium Workshop. June 2-3, 2001. Vancouver.
  90. Canadian Association of Pathologists: Testing for Hereditary cancer syndromes: June 15, 2001.
  91. Northwest Radiobiology/Molecular Oncology Review Course. Cancer Genetics Review. May 11, 2001.
  92. BC Surgeons Conference, December 2, 2000
  93. Genetics & Genomic "What you need to know but were not taught". The Annual BC Cancer Agency Clinical Cancer Conference, November 24, 2000
  94. New Century New Diagnostics, UBC 50th Golden Jubilee Conference, November 4, 2000
  95. Hereditary Cancers: Basic review and implications for gynecologic practice, D.A. Boyes Society, November 3, 2000
  96. Hereditary Cancer, UBC 50th Golden Jubilee Conference, November 4, 2000.
  97. Advances in the Genetics of GI Tumors. Pacific Northwest Society of Pathologists meeting, September 15, 2000
  98. Prophylactic Gastrectomy for Cure: International Gastric Cancer Linkage Consortium Meeting, Sienna It, June 3, 2000
  99. Familial Gastric Cancer: Cambridge Conference on Inherited Predisposition to Cancer: April 1999


last updated 2009-03-30
spacer
spacer
spacer
Logo
spacer
spacer
Copyright © 2014 Genetic Pathology Evaluation Centre All Rights Reserved; Last modified June 18, 2014